In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments and systems used use in the collection, preparation, and examination of specimens taken from the human body. This includes Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers, Oncology and Reproductive Health Diagnostics. Treponema Pallidum is the causative organism for Syphilis and cannot be cultivated in vitro, resulting in a need for specific IVD tests, rather than the more usual bacteriology testing. GlobalData uses proprietary data and analytics to provide a comprehensive report on the treponema pallidum tests devices market, including market shares of different players within New Zealand. Buy the latest report here.
Smarter leaders trust GlobalData
In 2023, GlobalData’s Market Model methodology determined that the leading player in the treponema pallidum tests market in New Zealand was Abbott Laboratories followed by Siemens Healthineers, F. Hoffmann-La Roche, H.U. Group, WerfenLife, Cambridge Nutritional Sciences, Bio-Rad Laboratories, Becton Dickinson and Co, DiaSorin, Sekisui Diagnostics, bioMerieux, Arlington Scientific and Cardinal Health.
The identification of the Treponema pallidum pathogen is usually performed by using Direct and Indirect detection methods. It includes Venereal Disease Research Laboratory (VDRL) Tests, Rapid Plasma Reagin (RPR) Tests, Unheated Serum Reagin (USR) Tests, Treponema Passive Particle Agglutination (TPPA) Tests, Treponema Pallidum Hemagglutination (TPHA) Tests, Fluorescent Treponemal Antibody Absorption (FTA-ABS) Tests, Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Tests and Other Tests. Direct Detection Methods: Direct detection methods include the detection of Treponema pallidum by microscopic examination of fluids and smears from lesions, histological examination of tissues, or nucleic acid amplification methods such as Polymerase Chain Reaction (PCR). Nucleic acid amplification methods are not standardized for the testing of Treponema pallidum as they are under investigation. Indirect Detection Methods: Indirect detection methods for Treponema pallidum include serological tests which are broadly classified into Non-treponemal and Treponemal tests. Non-Treponemal Tests: Non-Treponemal tests are used to detect the antibodies or biomarkers that occur as a result of the cellular damage caused due to the syphilis spirochete. Centers for Disease Control and Prevention (CDC) approved Non-treponemal standard tests which include the VDRL (Venereal Disease Research Laboratory) slide tests, the RPR (Rapid Plasma Reagin) card tests, the USR (Unheated Serum Reagin) tests and the TRUST (Toluidine Red Unheated Serum Test).
The value of the treponema pallidum tests devices market within New Zealand was expected to be over $0.6m in 2023.
For the latest complete market share analysis of treponema pallidum tests device market in New Zealand, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. Pipeline Products database is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
